THIS SITE IS INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

Prescribing information and adverse event reporting statement can be found in the footer

ASD

Overview

Autism is known as a "spectrum" disorder because there is wide variation in symptoms, skills and levels of impact people experience.

The saying, “If you’ve seen one child with autism, you’ve seen one child with autism”, aptly captures this fact - no two people with Autism Spectrum Disorder (ASD) are affected in exactly the same way and ASD is unique to the individual. Whereas previously, Autistic Disorder was a diagnostic subcategory of Pervasive Developmental Disorders, in DSM-5 (published in 2013) a single diagnostic classification of Autistic Spectrum Disorder is now used to describe a single condition with different levels of symptom severity in two core domains: (i) deficits in social communication and interaction and (ii) restrictive, repetitive behaviours, interests and activities. Importantly, DSM-5 now allows for a dual diagnosis of ASD and Attention Deficit Hyperactivity Disorder (ADHD) where both conditions co-exist.1

The estimated UK prevalence of ASD is 1% and because of its early onset, lifelong persistence, and high levels of associated impairment, it is recognised as a major public health concern.

There are many claims of a 'cure' for autism, all of which are without foundation. However, there are interventions that can help some of the core features of autism, some of the symptoms, behaviours and problems commonly associated with autism, and support families and carers.2 Many individuals with ASD have psychiatric symptoms that do not form part of the diagnostic criteria for the disorder; it is recognised that about 70% of individuals with ASD impairment may have one comorbid mental disorder and 40% may have two or more comorbid mental disorders. Medical conditions commonly associated with ASD include epilepsy, sleep problems and constipation.1 Identification of comorbidities may provide targets for specific interventions to reduce overall impairment and improve quality of life.

Upcoming Events

Flynn Pharma is committed to the delivery of high quality medical educational events that support the continued development of healthcare professionals - it's our way of helping you to help your patients. Don't miss out. Flynn continues to host a series of educational events and webinars around ASD and other neurodevelopmental disorders that are free for healthcare professionals to attend. Sign up to receive our latest updates.

2026 Events Coming Soon
2026 Events Coming Soon

Autism Spectrum Disorder - Continue Your Journey

References

  1. Diagnostic and Statistical Manual of Mental Disorders, 5th edition: DSM-5. American Psychiatric Association, 2017
  2. NICE Clinical guideline CG170 Autism spectrum disorder in under 19s: support and management. Published August 2013